Virax Biolabs science chief holds five option grants

Q: What stock options does VRAX Chief Scientific Officer Clement Monteil hold?

Clement Monteil directly holds options covering 60 ordinary shares at an exercise price of 310, 400 at 150, 800 at 17, 600 at 21.9, and 3,000 at 3.75. Their stated expiration dates range from December 7, 2032, to April 8, 2036.

A 3,000-option grant is the largest listed tranche and is scheduled to vest in equal thirds from 2027 through 2029.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Virax Biolabs Group Ltd reports that Chief Scientific Officer Clement Monteil directly holds five stock-option positions covering 60, 400, 800, 600 and 3,000 ordinary shares, with exercise prices of 310, 150, 17, 21.9 and 3.75, respectively. The options expire between December 7, 2032, and April 8, 2036. Footnotes state that each grant vests in equal thirds on scheduled annual dates and that vested portions become exercisable upon vesting.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Monteil Clement

Role Insider

Type	Security	Shares	Price	Value
holding	Stock Options ^F1	--	--	--
holding	Stock Options ^F2	--	--	--
holding	Stock Options ^F3	--	--	--
holding	Stock Options ^F4	--	--	--
holding	Stock Options ^F5	--	--	--

Holdings After Transaction: Stock Options — 4,860 contracts (Direct)

Footnotes (5)

F1. On December 7, 2022, the Company granted 60 stock options under the Company's 2022 Equity Incentive Plan. The options vest in equal thirds on December 7 of each of 2023, 2024 and 2025. The vested portions of such options will become exercisable upon vesting.
F2. On April 18, 2023, the Company granted 400 stock options under the Company's 2022 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2024, 2025 and 2026. The vested portions of such options will become exercisable upon vesting.
F3. On April 18, 2024, the Company granted 800 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.
F4. On April 8, 2025, the Company granted 600 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.
F5. On April 8, 2026, the Company granted 3,000 stock options under the Company's 2026 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2027, 2028 and 2029. The vested portions of such options will become exercisable upon vesting.

Key Figures

Options expiring December 7, 2032: 60 underlying ordinary shares; exercise price 310 Options expiring April 18, 2033: 400 underlying ordinary shares; exercise price 150 Options expiring April 18, 2034: 800 underlying ordinary shares; exercise price 17 +2 more

5 metrics

Options expiring December 7, 2032 60 underlying ordinary shares; exercise price 310 Granted December 7, 2022

Options expiring April 18, 2033 400 underlying ordinary shares; exercise price 150 Granted April 18, 2023

Options expiring April 18, 2034 800 underlying ordinary shares; exercise price 17 Granted April 18, 2024

Options expiring April 8, 2035 600 underlying ordinary shares; exercise price 21.9 Granted April 8, 2025

Options expiring April 8, 2036 3,000 underlying ordinary shares; exercise price 3.75 Granted April 8, 2026

Key Terms

vest in equal thirds, exercisable upon vesting, Equity Incentive Plan

3 terms

vest in equal thirds technical

"The options vest in equal thirds"

exercisable upon vesting technical

"will become exercisable upon vesting"

Equity Incentive Plan technical

"under the Company's 2022 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options does VRAX Chief Scientific Officer Clement Monteil hold?

Clement Monteil directly holds options covering 60 ordinary shares at an exercise price of 310, 400 at 150, 800 at 17, 600 at 21.9, and 3,000 at 3.75. Their stated expiration dates range from December 7, 2032, to April 8, 2036.

When do VRAX option grants vest?

Each grant vests in equal thirds on annual dates: December 7 for the 60-option grant, April 18 for the 400- and 800-option grants, and April 8 for the 600- and 3,000-option grants. The schedules run from 2023 through 2029, and vested portions become exercisable upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/21/2026 - 08:12 AM EDT Accepted by SEC EDGAR 10/21/2026 - 08:12 AM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Monteil Clement

(Last)

(First)

(Middle)

C/O VIRAX BIOLABS, BIOCITY GLASGOW

BO'NESS RD, NEWHOUSE

(Street)

LANARKSHIRE

MOTHERWELL

ML1 5UH

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/05/2026

3. Issuer Name and Ticker or Trading Symbol
Virax Biolabs Group Ltd [ VRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options	⁽¹⁾	12/07/2032	Ordinary Shares	60	$310	D
Stock Options	⁽²⁾	04/18/2033	Ordinary Shares	400	$150	D
Stock Options	⁽³⁾	04/18/2034	Ordinary Shares	800	$17	D
Stock Options	⁽⁴⁾	04/08/2035	Ordinary Shares	600	$21.9	D
Stock Options	⁽⁵⁾	04/08/2036	Ordinary Shares	3,000	$3.75	D

Explanation of Responses:

1. On December 7, 2022, the Company granted 60 stock options under the Company's 2022 Equity Incentive Plan. The options vest in equal thirds on December 7 of each of 2023, 2024 and 2025. The vested portions of such options will become exercisable upon vesting.

2. On April 18, 2023, the Company granted 400 stock options under the Company's 2022 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2024, 2025 and 2026. The vested portions of such options will become exercisable upon vesting.

3. On April 18, 2024, the Company granted 800 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.

4. On April 8, 2025, the Company granted 600 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

5. On April 8, 2026, the Company granted 3,000 stock options under the Company's 2026 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2027, 2028 and 2029. The vested portions of such options will become exercisable upon vesting.

	/s/ Clement Monteil	10/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR